| Literature DB >> 32537443 |
Peilin Wu1, Suqing Chen1, Bin Wu1, Junhong Chen1, Ge Lv2.
Abstract
Tyrosine kinase 2 (TYK2) deficiency was formerly defined in patients suffering from autosomal recessive hyperimmunoglobulin E syndrome (AR-HIES). In recent years, it was proposed that human TYK2 deficiency is probably not a common cause of the AR-HIES but a distinctive illness object. In the current work, a recessive TYK2 deficiency is reported in a patient suffering from BCG disease and recurrent respiratory infection. It was implied that this patient carried novel missense homozygous mutation (c.2395G>A, p. G799R) in the TYK2. Both the in vivo and in vitro experiments indicated the inhibition effects of the c.2395G>A homozygous mutation on the TYK2 gene and protein expression. By literature review, we summarized the clinical manifestations, gene mutations, and related cytokine responses of formerly reported patients possessing TYK2 deficiency. The core manifestation of these patients is infected by intracellular pathogens, such as mycobacteria and/or viruses. Therefore, the possibility of TYK2 deficiency should be considered when a patient has repeated intracellular bacteria (including tuberculosis bacillus infection), repeated viral infection or eczema.Entities:
Keywords: BCG; TYK2 deficiency; hyperimmunoglobulin E syndrome; mutation; primary immunodeficiency
Year: 2020 PMID: 32537443 PMCID: PMC7267021 DOI: 10.3389/fped.2020.00253
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Immunologic parameters of our patient.
| Absolute lymphocyte count,/mm3 | 5,550 | 800–4,000 |
| Absolute eosinophil count, /mm3 | 270 | 20–500 |
| IgG, g/L | 3.43 | 3–10 |
| IgM, g/L | 1.94 | 0.45–2.39 |
| IgA, g/L | 0.23 | 0.14–1.08 |
| IgE, IU/ml | 27.4 | ≤ 49 |
| T cells, CD3+, % | 63.2 | 53.88–72.87 |
| B cells, CD19+, % | 26.6 | 7.21–20.90 |
| CD4+ cells, % | 35.9 | 24.08–42.52 |
| CD8+ cells, % | 19.3 | 19.00–32.51 |
| Natural Killer cells, CD3−CD16 /CD56+, % | 3.6 | 13.23–26.39 |
Pathogen detection results.
| IgM to respiratory syncytial virus | negative (-) | negative (-) |
| IgM to adenovirus | negative (–) | negative (–) |
| IgM to influenza A virus | positive (+) | negative (–) |
| IgM to influenza B virus | positive (+) | negative (–) |
| IgM to parainfluenza virus | negative (–) | negative (–) |
| IgM to M. pneumoniae | positive (+) | negative (–) |
| IgM to M. tuberculosis | negative (–) | negative (–) |
| IgM to legionella pneumophila | negative (–) | negative (–) |
| M. pneumoniae antibody (mp ab) | 1: 160 | 1: 40 |
Figure 1A homozygous missense mutation in exon 17 of the TYK2 gene in our patient.
Figure 2The expression of TYK2 in these family members. (A) The qRT-PCR results of the patient and health control. (B) Western blot analysis results of Tyk2 protein in patient and health control.
Figure 3Expression of TYK2 in wild type and c.2395G>A mutant HEK293T cell line. (A) The sanger analysis results of wild type and c.2395G>A mutant HEK293T cell; (B) mRNA expression of FLAG-TYK2 and TYK2-GFP in both wild type and c.2395G>A mutant HEK293T cell; (C) Western blot analysis results of FLAG-TYK2 and TYK2-GFP in both wild type and c.2395G>A mutant HEK293T cell.
Information about reported TYK2-deficient patients.
| P1 | Minegishi | M | Japan | 22 | yes | yes | yes | HSV, PI3, MC | BCG | C. albicans | yes | Exon 4 c.550_553delGCTT | C70HfsX21 |
| P2 | Kreins | M | Turkey | 17 | no | no | no | VZV | BCG, | no | yes | Exon 16 c.2303_2311del | L767X |
| P3 | Kreins | F | Morocco | 14 | no | no | no | no | no | yes | Exon23 c.3318_3319insC | T1106HfsX4 | |
| P4 | Kreins | M | Morocco | 14 | no | no | no | unknown | unknown | no | yes | Exon23 c.3318_3319insC | T1106HfsX4 |
| P5 | Kreins | M | Iran | 5 | no | no | no | no | BCG | no | yes | Exon5 c.462G>T | E154X |
| P6 | Kreins | F | Iran | 2 | no | no | no | yes | BCG | no | yes | Exon5 c.462G>T | E154X |
| P7 | Kreins | F | Iran | 9 | no | no | no | no | no | yes | Exon3 c.149delC | S50HfsX1 | |
| P8 | Kreins | M | Argentina | 11 | no | no | no | HSV | No | no | yes | Exon13 c.1912 C>T | R638X |
| P9 | Fuchs | M | Kurdish | 5 | yes | yes | yes | no | No | no | no | Exon7 c.647delC | P216RfsX14 |
| P10 | Nemoto | M | unknown | 15 | no | no | no | EBV-associated B-cell lymphoma, varicella | No | no | yes | compound heterozygous mutations c.209_212 del GCTT /c.691 C > T | C70SfsX21/R231W |
| P11 | Nemoto | F | unknown | 14 | no | no | no | EBV-associated B-cell lymphoma, Varicella | Unknown | no | yes | compound heterozygous mutations c.209_212 del GCTT /c.691 C > T | C70SfsX21/R231W |
| P12 | Peilin | M | China | 2 | no | no | no | Influenza virus | MP, BCG | no | yes | Exon17 c.2395G>A | G799R |
| Total | M:F = 8:4 | 10.8 | 2/12 (0.17) | 2/12 (0.17) | 2/12 (0.17) | 7/12 (0.58) | 7/12 (0.58) | 1/12 (0.08) | 11/12 (0.92) |
BCG, Bacillus Calmette – Guerin; MP, mycoplasma pneumonia.